Tradestie Institutional Equity Comparison Engine

VRCA vs DMAC โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

DMAC Overall Edge

DMAC Captures Institutional Edge (3โ€“0 Pillars ยท 7โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to DiaMedica Therapeutics Inc. Common Stock (DMAC) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, VRCA trades at N/M Forward P/E with -87.2% operating margin (-53.9% YoY revenue) versus DMAC at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, VRCA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against DMAC sits in SURGE (14th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
VRCA N/M vs DMAC N/M Fwd P/E
Growth & Margin Winner DMAC
Op Margin -87.2% vs 0.0% ยท YoY -53.9% vs +0.0%
Momentum & Technical Winner DMAC
1Y -13.1% vs +55.3% ยท 52W Pos 4% vs 55%
Options & Structure Winner DMAC
UNCLASSIFIED (N/A IV) vs SURGE (14th %ile IV)
VRCA NASDAQ
Verrica Pharmaceuticals Inc. Common Stock
Pharmaceutical Preparations
$3.37
-5.48% 1D
Market Cap $63.9M
1M Return -6.4%
1Y Return -13.05%
Forward P/E N/M
Unified AI Score
38.5 / 100 SELL
Tech 41.0 Fund 37.0 Flow 50.0 Mom 44.0
DMAC NASDAQ
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.41
-4.27% 1D
Market Cap $503.1M
1M Return +11.16%
1Y Return +55.26%
Forward P/E N/M
Unified AI Score
46.3 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 65.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: VRCA -13.05% DMAC +55.26% Spread: +68.31 pp (DMAC Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period VRCA Revenue DMAC Revenue VRCA Op. Margin DMAC Op. Margin Margin Edge
FY2018 N/A $0M N/A -1352.2% DMAC
FY2021 $10M N/A -257.6% N/A VRCA
FY2022 $10M N/A -235.8% N/A VRCA
FY2023 $10M N/A -1283.4% N/A VRCA
FY2024 $10M N/A -871.3% N/A VRCA
FY2025 $40M N/A -34.2% N/A VRCA

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: VRCA (1) vs DMAC (7)
Institutional Metric VRCA DMAC Criterion Row Winner
Market Capitalization Scale $63.9M $503.1M Larger Scale DMAC
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -53.9% +0.0% Higher Growth DMAC
Operating Margin (TTM) Profitability -87.2% 0.0% Higher Margin DMAC
Net Profit Margin Profitability -102.8% 0.0% Higher Margin DMAC
Return on Equity (ROE) Capital Efficiency -240.4% -114.6% Higher ROE DMAC
52-Week Range Position Momentum 4% ($3โ€“$10) 55% ($5โ€“$11) Stronger Trend DMAC
Beta / 30D Volatility Risk Regime 1.93ฮฒ ยท 92% Vol 1.74ฮฒ ยท 98% Vol Lower Realized Risk VRCA
Unified Institutional Score Composite Signal 38.5 / 100 (SELL) 46.3 / 100 (HOLD) Higher Composite DMAC

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full VRCA vs DMAC Buy Guide
VRCA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live VRCA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
DMAC SURGE
8d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 14th %ile
IV Regime Compressed (<25th %ile)
Live DMAC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither VRCA nor DMAC registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.